Randomized Multicenter Phase II Trial of Bolus Plus Infusional Fluorouracil/Leucovorin Compared With Fluorouracil/Leucovorin Plus Oxaliplatin As Third-Line Treatment of Patients With Advanced Colorectal Cancer

Abstract

In patients with metastatic CRC, the FOLFOX4 regimen was superior to LV5FU2 with a higher response rate and time to disease progression. FOLFOX4 is an effective regimen even after disease progression on two previous chemotherapy regimens with fluoropyrimidines and irinotecan.

Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer

“…In the current setting, the reported rate (64%) of patients that manifested OXLIPN after administration of the formal FOLFOX-4 regimen is quite similar to that previously reported in several trials [12,13]. As in most other previous publications [4,13], the majority of our patients experienced mild or moderate (grade 1Á2) OXLIPN.…”

Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report

“…Single agent oxaliplatin was essentially as inactive as infused 5-FU/LV. These data were essentially con-firmed when infused 5-FU/LV was compared with FOLFOX after progression on sequential fluoropyrimidine and irinotecan [36]. Similar data were also reported for treatment with oxaliplatin in combination with capecitabine (Xelox) after progression on irinotecan/5-FU/LV [37].…”

Current role of antibody therapy in patients with metastatic colorectal cancer

“…Second-line therapy after first-line doublet generates RRs of 5-20%, increases TTP to 4-6 months (Rothenberg et al, 2003;Grothey et al, 2004;Kemeny et al, 2004;Tournigand et al, 2004;Pfeiffer et al, 2006) and also adds to a prolonged OS. A recent review pointed out that OS was significantly correlated with the percentage of patients who received all three drugs .…”